CACNA1G and encephalopathy, progressive, early-onset, with brain edema and/or leukoencephalopathy: Given that Cav3.1 is an emerging target for treating Dravet syndrome, we conducted more detailed patch-clamp electrophysiology studies to illuminate the biophysical properties of the inhibitory effects at this channel.